Posts Tagged ‘PD-1’
Today’s post was written by Bert E. Thomas IV, PhD, MBA, CEO of the Sarcoma Foundation of America. There was a long period of time where there seemed to be little to no progress in finding ways to battle the forgotten cancer known as sarcoma. This period of time lasted for decades, though it probably felt more like centuries to the patients and families that were desperately looking for treatment options that never seemed to come. And while sarcoma still takes too many of our loved ones from us, progress in our fight against this terrible disease is finally being… Read More »
Dear Sarcoma Foundation of America Supporter, As the calendar takes us into the holiday season, we take the time to reflect on the year that has passed. In the sarcoma community, 2016 has been a year of hope and progress. Two new sarcoma drugs have been approved, one drug for Leiomyosarcoma and Liposarcoma patients and another approved broadly for Soft Tissue Sarcoma patients. These new therapeutic options give us continued hope for better patient outcomes and represent the progress that sarcoma researchers have made over the last decade. The type of hope and progress that the sarcoma community experienced in… Read More »
DEC. 22, 2014 – ANN ARBOR, MICH. – Focused on their mission to identify new treatments for sarcoma, an uncommon cancer, SARC has leveraged a generous donation to secure the support of the Sarcoma Foundation of America (SFA) and the What Would Willie Want Foundation (QuadW) in a collaborative effort to support a new multi-institutional clinical trial of an anti-PD1 agent. The company who is providing their drug and support for the study of soft tissue sarcoma agreed to provide their drug to study bone sarcomas if additional funding could be secured. SARC secured generous commitments from the Sarcoma Foundation… Read More »